Insider Transactions in Q1 2025 at Acrivon Therapeutics, Inc. (ACRV)
Insider Transaction List (Q1 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 21
2025
|
Peter Blume Jensen President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
19,904
-0.86%
|
$99,520
$5.54 P/Share
|
|
Feb 14
2025
|
Katharine Peterson Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
116
-2.56%
|
$580
$5.42 P/Share
|
|
Feb 14
2025
|
Rasmus Holm Jorgensen Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
434
-1.64%
|
$2,170
$5.42 P/Share
|
|
Feb 14
2025
|
Mary Miller Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
217
-0.58%
|
$1,085
$5.42 P/Share
|
|
Feb 14
2025
|
Peter Blume Jensen President and CEO |
SELL
Payment of exercise price or tax liability
|
Indirect |
579
-0.18%
|
$2,895
$5.42 P/Share
|
|
Feb 14
2025
|
Peter Blume Jensen President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
37,152
-1.59%
|
$185,760
$5.42 P/Share
|
|
Feb 14
2025
|
Eric Devroe Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
724
-1.07%
|
$3,620
$5.42 P/Share
|
|
Feb 14
2025
|
Erick Gamelin Chief Development Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
469
-2.77%
|
$2,345
$5.42 P/Share
|
|
Jan 17
2025
|
Mary Miller Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
659
-1.74%
|
$3,295
$5.78 P/Share
|